Spinal-Cord Injury: Lentiviral-Vectors and Biomaterials: Comparison
View Latest Version
Please note this is a comparison between Version 1 by Ciara Shortiss and Version 2 by Beatrix Zheng.

Spinal cord injury (SCI) is a devastating trauma that can cause permanent disability, life-long chronic issues for sufferers and is a big socioeconomic burden. Therapies that target multiple different cellular and molecular mechanisms prove to be a superior approach in attempts at regeneration. Studies indicate that a combination of biomaterials and LVs is more effective than either approach alone. 

  • spinal cord injury
  • gene therapy
  • lentiviral vector
  • bioscaffold
  • biomaterial
Please wait, diff process is still running!

References

  1. NSCISC. National Spinal Cord Injury Statistical Center. Facts and Figures at a Glance; University of Alabama at Birmingham: Birmingham, AL, USA, 2021.
  2. Finnerup, N.B. Neuropathic pain and spasticity: Intricate consequences of spinal cord injury. Spinal Cord 2017, 55, 1046–1050.Finnerup, N.B. Neuropathic pain and spasticity: Intricate consequences of spinal cord injury. Spinal Cord 2017, 55, 1046–1050, doi:10.1038/sc.2017.70.
  3. Binder, H. Chapter 35—Traumatic spinal cord injury. In Handbook of Clinical Neurology; Barnes, M.P., Good, D.C., Eds.; Elsevier: Amsterdam, The Netherlands, 2013; Volume 110, pp. 411–426.
  4. Krause, J.S.; Dismuke-Greer, C.E.; Reed, K.S.; Li, C. Employment status, hours working, and gainful earnings after spinal cord injury: Relationship with pain, prescription medications for pain, and nonprescription opioid use. Spinal Cord 2020, 58, 275–283.Krause, J.S.; Dismuke-Greer, C.E.; Reed, K.S.; Li, C. Employment status, hours working, and gainful earnings after spinal cord injury: Relationship with pain, prescription medications for pain, and nonprescription opioid use. Spinal Cord 2020, 58, 275–283, doi:10.1038/s41393-019-0374-1.
  5. Ashammakhi, N.; Kim, H.J.; Ehsanipour, A.; Bierman, R.D.; Kaarela, O.; Xue, C.; Khademhosseini, A.; Seidlits, S.K. Regenerative Therapies for Spinal Cord Injury. Tissue Eng. Part B Rev. 2019, 25, 471–491.Ashammakhi, N.; Kim, H.J.; Ehsanipour, A.; Bierman, R.D.; Kaarela, O.; Xue, C.; Khademhosseini, A.; Seidlits, S.K. Regenerative Therapies for Spinal Cord Injury. Tissue Eng. Part B Rev. 2019, 25, 471–491, doi:10.1089/ten.TEB.2019.0182.
  6. Dumont, R.J.; Okonkwo, D.O.; Verma, S.; Hurlbert, R.J.; Boulos, P.T.; Ellegala, D.B.; Dumont, A.S. Acute spinal cord injury, part I: Pathophysiologic mechanisms. Clin. Neuropharmacol. 2001, 24, 254–264.Dumont, R.J.; Okonkwo, D.O.; Verma, S.; Hurlbert, R.J.; Boulos, P.T.; Ellegala, D.B.; Dumont, A.S. Acute spinal cord injury, part I: Pathophysiologic mechanisms. Clin. Neuropharmacol. 2001, 24, 254–264, doi:10.1097/00002826-200109000-00002.
  7. O’Shea, T.M.; Burda, J.E.; Sofroniew, M.V. Cell biology of spinal cord injury and repair. J. Clin. Investig. 2017, 127, 3259–3270.O’Shea, T.M.; Burda, J.E.; Sofroniew, M.V. Cell biology of spinal cord injury and repair. J. Clin. Investig. 2017, 127, 3259–3270, doi:10.1172/JCI90608.
  8. Oyinbo, C.A. Secondary injury mechanisms in traumatic spinal cord injury: A nugget of this multiply cascade. Acta Neurobiol. Exp. 2011, 71, 281–299.
  9. Tran, A.P.; Warren, P.M.; Silver, J. The Biology of Regeneration Failure and Success After Spinal Cord Injury. Physiol. Rev. 2018, 98, 881–917.Tran, A.P.; Warren, P.M.; Silver, J. The Biology of Regeneration Failure and Success After Spinal Cord Injury. Physiol. Rev. 2018, 98, 881–917, doi:10.1152/physrev.00017.2017.
  10. Alizadeh, A.; Dyck, S.M.; Karimi-Abdolrezaee, S. Traumatic Spinal Cord Injury: An Overview of Pathophysiology, Models and Acute Injury Mechanisms. Front. Neurol. 2019, 10, 282.Alizadeh, A.; Dyck, S.M.; Karimi-Abdolrezaee, S. Traumatic Spinal Cord Injury: An Overview of Pathophysiology, Models and Acute Injury Mechanisms. Front. Neurol. 2019, 10, 282, doi:10.3389/fneur.2019.00282.
  11. Bradbury, E.J.; Burnside, E.R. Moving beyond the glial scar for spinal cord repair. Nat. Commun. 2019, 10, 3879.Bradbury, E.J.; Burnside, E.R. Moving beyond the glial scar for spinal cord repair. Nat. Commun. 2019, 10, 3879, doi:10.1038/s41467-019-11707-7.
  12. Walthers, C.M.; Seidlits, S.K. Gene delivery strategies to promote spinal cord repair. Biomark. Insights 2015, 10, 11–29.Walthers, C.M.; Seidlits, S.K. Gene delivery strategies to promote spinal cord repair. Biomark. Insights 2015, 10, 11–29, doi:10.4137/bmi.S20063.
  13. Uchida, K.; Nakajima, H.; Guerrero, A.R.; Johnson, W.E.B.; Masri, W.E.; Baba, H. Gene therapy strategies for the treatment of spinal cord injury. Ther. Deliv. 2014, 5, 591–607.Uchida, K.; Nakajima, H.; Guerrero, A.R.; Johnson, W.E.B.; Masri, W.E.; Baba, H. Gene therapy strategies for the treatment of spinal cord injury. Ther. Deliv. 2014, 5, 591–607, doi:10.4155/tde.14.20.
  14. Seidlits, S.K.; Gower, R.M.; Shepard, J.A.; Shea, L.D. Hydrogels for lentiviral gene delivery. Expert Opin. Drug Deliv. 2013, 10, 499–509.Seidlits, S.K.; Gower, R.M.; Shepard, J.A.; Shea, L.D. Hydrogels for lentiviral gene delivery. Expert Opin. Drug Deliv. 2013, 10, 499–509, doi:10.1517/17425247.2013.764864.
  15. Milone, M.C.; O’Doherty, U. Clinical use of lentiviral vectors. Leukemia 2018, 32, 1529–1541.Milone, M.C.; O’Doherty, U. Clinical use of lentiviral vectors. Leukemia 2018, 32, 1529–1541, doi:10.1038/s41375-018-0106-0.
  16. Campochiaro, P.A.; Lauer, A.K.; Sohn, E.H.; Mir, T.A.; Naylor, S.; Anderton, M.C.; Kelleher, M.; Harrop, R.; Ellis, S.; Mitrophanous, K.A. Lentiviral Vector Gene Transfer of Endostatin/Angiostatin for Macular Degeneration (GEM) Study. Hum. Gene Ther. 2017, 28, 99–111.Campochiaro, P.A.; Lauer, A.K.; Sohn, E.H.; Mir, T.A.; Naylor, S.; Anderton, M.C.; Kelleher, M.; Harrop, R.; Ellis, S.; Mitrophanous, K.A. Lentiviral Vector Gene Transfer of Endostatin/Angiostatin for Macular Degeneration (GEM) Study. Hum. Gene Ther. 2017, 28, 99–111, doi:10.1089/hum.2016.117.
  17. Thomas, A.M.; Palma, J.L.; Shea, L.D. Sponge-mediated lentivirus delivery to acute and chronic spinal cord injuries. J. Control. Release 2015, 204, 1–10.Thomas, A.M.; Palma, J.L.; Shea, L.D. Sponge-mediated lentivirus delivery to acute and chronic spinal cord injuries. J. Control. Release 2015, 204, 1–10, doi:10.1016/j.jconrel.2015.02.032.
  18. Tuinstra, H.M.; Aviles, M.O.; Shin, S.; Holland, S.J.; Zelivyanskaya, M.L.; Fast, A.G.; Ko, S.Y.; Margul, D.J.; Bartels, A.K.; Boehler, R.M.; et al. Multifunctional, multichannel bridges that deliver neurotrophin encoding lentivirus for regeneration following spinal cord injury. Biomaterials 2012, 33, 1618–1626.Tuinstra, H.M.; Aviles, M.O.; Shin, S.; Holland, S.J.; Zelivyanskaya, M.L.; Fast, A.G.; Ko, S.Y.; Margul, D.J.; Bartels, A.K.; Boehler, R.M.; et al. Multifunctional, multichannel bridges that deliver neurotrophin encoding lentivirus for regeneration following spinal cord injury. Biomaterials 2012, 33, 1618–1626, doi:10.1016/j.biomaterials.2011.11.002.
  19. Meunier, A.; Pohl, M. Lentiviral vectors for gene transfer into the spinal cord glial cells. Gene Ther. 2009, 16, 476–482.Meunier, A.; Pohl, M. Lentiviral vectors for gene transfer into the spinal cord glial cells. Gene Ther. 2009, 16, 476–482, doi:10.1038/gt.2009.22.
  20. Merten, O.-W.; Hebben, M.; Bovolenta, C. Production of lentiviral vectors. Mol. Ther. Methods Clin. Dev. 2016, 3, 16017.Merten, O.-W.; Hebben, M.; Bovolenta, C. Production of lentiviral vectors. Mol. Ther. Methods Clin. Dev. 2016, 3, 16017–16017, doi:10.1038/mtm.2016.17.
  21. Nori, S.; Khazaei, M.; Ahuja, C.S.; Yokota, K.; Ahlfors, J.-E.; Liu, Y.; Wang, J.; Shibata, S.; Chio, J.; Hettiaratchi, M.H.; et al. Human Oligodendrogenic Neural Progenitor Cells Delivered with Chondroitinase ABC Facilitate Functional Repair of Chronic Spinal Cord Injury. Stem Cell Rep. 2018, 11, 1433–1448.Nori, S.; Khazaei, M.; Ahuja, C.S.; Yokota, K.; Ahlfors, J.-E.; Liu, Y.; Wang, J.; Shibata, S.; Chio, J.; Hettiaratchi, M.H.; et al. Human Oligodendrogenic Neural Progenitor Cells Delivered with Chondroitinase ABC Facilitate Functional Repair of Chronic Spinal Cord Injury. Stem Cell Rep. 2018, 11, 1433–1448, doi:10.1016/j.stemcr.2018.10.017.
  22. Wang, D.; Li, J.; Tran, K.; Burt, D.R.; Zhong, L.; Gao, G. Slow Infusion of Recombinant Adeno-Associated Viruses into the Mouse Cerebrospinal Fluid Space. Hum. Gene Ther. Methods 2018, 29, 75–85.Wang, D.; Li, J.; Tran, K.; Burt, D.R.; Zhong, L.; Gao, G. Slow Infusion of Recombinant Adeno-Associated Viruses into the Mouse Cerebrospinal Fluid Space. Hum. Gene Ther. Methods 2018, 29, 75–85, doi:10.1089/hgtb.2017.250.
  23. Kimura, E.; Li, S.; Gregorevic, P.; Fall, B.M.; Chamberlain, J.S. Dystrophin delivery to muscles of mdx mice using lentiviral vectors leads to myogenic progenitor targeting and stable gene expression. Mol. Ther. 2010, 18, 206–213.Kimura, E.; Li, S.; Gregorevic, P.; Fall, B.M.; Chamberlain, J.S. Dystrophin delivery to muscles of mdx mice using lentiviral vectors leads to myogenic progenitor targeting and stable gene expression. Mol. Ther. 2010, 18, 206–213, doi:10.1038/mt.2009.253.
  24. Vranckx, L.S.; Demeulemeester, J.; Debyser, Z.; Gijsbers, R. Towards a Safer, More Randomized Lentiviral Vector Integration Profile Exploring Artificial LEDGF Chimeras. PLoS ONE 2016, 11, e0164167.Vranckx, L.S.; Demeulemeester, J.; Debyser, Z.; Gijsbers, R. Towards a Safer, More Randomized Lentiviral Vector Integration Profile Exploring Artificial LEDGF Chimeras. PLoS ONE 2016, 11, e0164167, doi:10.1371/journal.pone.0164167.
  25. Schröder, A.R.W.; Shinn, P.; Chen, H.; Berry, C.; Ecker, J.R.; Bushman, F. HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots. Cell 2002, 110, 521–529.Schröder, A.R.W.; Shinn, P.; Chen, H.; Berry, C.; Ecker, J.R.; Bushman, F. HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots. Cell 2002, 110, 521–529, doi:10.1016/S0092-8674(02)00864-4.
  26. McCarty, D.M.; Young, S.M., Jr.; Samulski, R.J. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu. Rev. Genet. 2004, 38, 819–845.McCarty, D.M.; Young, S.M., Jr.; Samulski, R.J. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu. Rev. Genet. 2004, 38, 819–845, doi:10.1146/annurev.genet.37.110801.143717.
  27. Deyle, D.R.; Russell, D.W. Adeno-associated virus vector integration. Curr. Opin. Mol. Ther. 2009, 11, 442–447.
  28. Burnside, E.R.; De Winter, F.; Didangelos, A.; James, N.D.; Andreica, E.-C.; Layard-Horsfall, H.; Muir, E.M.; Verhaagen, J.; Bradbury, E.J. Immune-evasive gene switch enables regulated delivery of chondroitinase after spinal cord injury. Brain 2018, 141, 2362–2381.Burnside, E.R.; De Winter, F.; Didangelos, A.; James, N.D.; Andreica, E.-C.; Layard-Horsfall, H.; Muir, E.M.; Verhaagen, J.; Bradbury, E.J. Immune-evasive gene switch enables regulated delivery of chondroitinase after spinal cord injury. Brain 2018, 141, 2362–2381, doi:10.1093/brain/awy158.
  29. Das, A.T.; Tenenbaum, L.; Berkhout, B. Tet-On Systems For Doxycycline-inducible Gene Expression. Curr. Gene Ther. 2016, 16, 156–167.Das, A.T.; Tenenbaum, L.; Berkhout, B. Tet-On Systems For Doxycycline-inducible Gene Expression. Curr. Gene Ther. 2016, 16, 156–167, doi:10.2174/1566523216666160524144041.
  30. Blits, B.; Bunge, M.B. Direct Gene Therapy for Repair of the Spinal Cord. J. Neurotrauma 2006, 23, 508–520.Blits, B.; Bunge, M.B. Direct Gene Therapy for Repair of the Spinal Cord. J. Neurotrauma 2006, 23, 508–520, doi:10.1089/neu.2006.23.508.
  31. Kruzik, A.; Fetahagic, D.; Hartlieb, B.; Dorn, S.; Koppensteiner, H.; Horling, F.M.; Scheiflinger, F.; Reipert, B.M.; de la Rosa, M. Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors. Mol. Ther. Methods Clin. Dev. 2019, 14, 126–133.Kruzik, A.; Fetahagic, D.; Hartlieb, B.; Dorn, S.; Koppensteiner, H.; Horling, F.M.; Scheiflinger, F.; Reipert, B.M.; de la Rosa, M. Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors. Mol. Ther. Methods Clin. Dev. 2019, 14, 126–133, doi:10.1016/j.omtm.2019.05.014.
  32. Annoni, A.; Gregori, S.; Naldini, L.; Cantore, A. Modulation of immune responses in lentiviral vector-mediated gene transfer. Cell. Immunol. 2019, 342, 103802.Annoni, A.; Gregori, S.; Naldini, L.; Cantore, A. Modulation of immune responses in lentiviral vector-mediated gene transfer. Cell. Immunol. 2019, 342, 103802, doi:10.1016/j.cellimm.2018.04.012.
  33. Trono, D. Lentiviral vectors: Turning a deadly foe into a therapeutic agent. Gene Ther 2000, 7, 20–23.Trono, D. Lentiviral vectors: Turning a deadly foe into a therapeutic agent. Gene Ther 2000, 7, 20–23, doi:10.1038/sj.gt.3301105.
  34. Tolmachov, O.; Tolmachova, T.; Al-Allaf, F. Designing Lentiviral Gene Vectors; IntechOpen: London, UK, 2011.
  35. Loy, D.N.; Crawford, C.H.; Darnall, J.B.; Burke, D.A.; Onifer, S.M.; Whittemore, S.R. Temporal progression of angiogenesis and basal lamina deposition after contusive spinal cord injury in the adult rat. J. Comp. Neurol. 2002, 445, 308–324.Loy, D.N.; Crawford, C.H.; Darnall, J.B.; Burke, D.A.; Onifer, S.M.; Whittemore, S.R. Temporal progression of angiogenesis and basal lamina deposition after contusive spinal cord injury in the adult rat. J. Comp. Neurol. 2002, 445, 308–324, doi:10.1002/cne.10168.
  36. Haggerty, A.E.; Maldonado-Lasunción, I.; Oudega, M. Biomaterials for revascularization and immunomodulation after spinal cord injury. Biomed. Mater. 2018, 13, 044105.Haggerty, A.E.; Maldonado-Lasunción, I.; Oudega, M. Biomaterials for revascularization and immunomodulation after spinal cord injury. Biomed. Mater. 2018, 13, 044105, doi:10.1088/1748-605X/aaa9d8.
  37. Koichi, M.; Noriko, M.; Takashi, S. Gene Delivery into the Central Nervous System (CNS) Using AAV Vectors; IntechOpen: London, UK, 2015.Koichi, M.; Noriko, M.; Takashi, S. Gene Delivery into the Central Nervous System (CNS) Using AAV Vectors; IntechOpen: London, UK 2015, doi:10.5772/61638.
  38. Leibinger, M.; Zeitler, C.; Gobrecht, P.; Andreadaki, A.; Gisselmann, G.; Fischer, D. Transneuronal delivery of hyper-interleukin-6 enables functional recovery after severe spinal cord injury in mice. Nat. Commun. 2021, 12, 391.Leibinger, M.; Zeitler, C.; Gobrecht, P.; Andreadaki, A.; Gisselmann, G.; Fischer, D. Transneuronal delivery of hyper-interleukin-6 enables functional recovery after severe spinal cord injury in mice. Nat. Commun. 2021, 12, 391–391, doi:10.1038/s41467-020-20112-4.
  39. Stepankova, K.; Jendelova, P.; Machova Urdzikova, L. Planet of the AAVs: The Spinal Cord Injury Episode. Biomedicines 2021, 9, 613.Stepankova, K.; Jendelova, P.; Machova Urdzikova, L. Planet of the AAVs: The Spinal Cord Injury Episode. Biomedicines 2021, 9, 613, doi:10.3390/biomedicines9060613.
  40. Liu, S.; Xie, Y.-Y.; Wang, B. Role and prospects of regenerative biomaterials in the repair of spinal cord injury. Neural Regen. Res. 2019, 14, 1352–1363.Liu, S.; Xie, Y.-Y.; Wang, B. Role and prospects of regenerative biomaterials in the repair of spinal cord injury. Neural Regen. Res. 2019, 14, 1352–1363, doi:10.4103/1673-5374.253512.
  41. Raut, S.D.; Lei, P.; Padmashali, R.M.; Andreadis, S.T. Fibrin-mediated lentivirus gene transfer: Implications for lentivirus microarrays. J. Control. Release 2010, 144, 213–220.Raut, S.D.; Lei, P.; Padmashali, R.M.; Andreadis, S.T. Fibrin-mediated lentivirus gene transfer: Implications for lentivirus microarrays. J. Control. Release 2010, 144, 213–220, doi:10.1016/j.jconrel.2010.02.009.
  42. Wu, H.F.; Cen, J.S.; Zhong, Q.; Chen, L.; Wang, J.; Deng, D.Y.; Wan, Y. The promotion of functional recovery and nerve regeneration after spinal cord injury by lentiviral vectors encoding Lingo-1 shRNA delivered by Pluronic F-127. Biomaterials 2013, 34, 1686–1700.Wu, H.F.; Cen, J.S.; Zhong, Q.; Chen, L.; Wang, J.; Deng, D.Y.; Wan, Y. The promotion of functional recovery and nerve regeneration after spinal cord injury by lentiviral vectors encoding Lingo-1 shRNA delivered by Pluronic F-127. Biomaterials 2013, 34, 1686–1700, doi:10.1016/j.biomaterials.2012.11.013.
  43. Padmashali, R.M.; Andreadis, S.T. Engineering fibrinogen-binding VSV-G envelope for spatially- and cell-controlled lentivirus delivery through fibrin hydrogels. Biomaterials 2011, 32, 3330–3339.Padmashali, R.M.; Andreadis, S.T. Engineering fibrinogen-binding VSV-G envelope for spatially- and cell-controlled lentivirus delivery through fibrin hydrogels. Biomaterials 2011, 32, 3330–3339, doi:10.1016/j.biomaterials.2011.01.035.
  44. Shin, S.; Shea, L.D. Lentivirus immobilization to nanoparticles for enhanced and localized delivery from hydrogels. Mol. Ther. 2010, 18, 700–706.Shin, S.; Shea, L.D. Lentivirus immobilization to nanoparticles for enhanced and localized delivery from hydrogels. Mol. Ther. 2010, 18, 700–706, doi:10.1038/mt.2009.300.
  45. Thomas, A.M.; Gomez, A.J.; Palma, J.L.; Yap, W.T.; Shea, L.D. Heparin-chitosan nanoparticle functionalization of porous poly(ethylene glycol) hydrogels for localized lentivirus delivery of angiogenic factors. Biomaterials 2014, 35, 8687–8693.Thomas, A.M.; Gomez, A.J.; Palma, J.L.; Yap, W.T.; Shea, L.D. Heparin-chitosan nanoparticle functionalization of porous poly(ethylene glycol) hydrogels for localized lentivirus delivery of angiogenic factors. Biomaterials 2014, 35, 8687–8693, doi:10.1016/j.biomaterials.2014.06.027.
  46. Thomas, A.M.; Shea, L.D. Polysaccharide-modified scaffolds for controlled lentivirus delivery in vitro and after spinal cord injury. J. Control. Release Off. J. Control. Release Soc. 2013, 170, 421–429.Thomas, A.M.; Shea, L.D. Polysaccharide-modified scaffolds for controlled lentivirus delivery in vitro and after spinal cord injury. J. Control. Release Off. J. Control. Release Soc. 2013, 170, 421–429, doi:10.1016/j.jconrel.2013.06.013.
  47. Shrimali, P.; Peter, M.; Singh, A.; Dalal, N.; Dakave, S.; Chiplunkar, S.V.; Tayalia, P. Efficient in situ gene delivery via PEG diacrylate matrices. Biomater. Sci. 2018, 6, 3241–3250.Shrimali, P.; Peter, M.; Singh, A.; Dalal, N.; Dakave, S.; Chiplunkar, S.V.; Tayalia, P. Efficient in situ gene delivery via PEG diacrylate matrices. Biomater. Sci. 2018, 6, 3241–3250, doi:10.1039/C8BM00916C.
  48. Shin, S.; Tuinstra, H.M.; Salvay, D.M.; Shea, L.D. Phosphatidylserine immobilization of lentivirus for localized gene transfer. Biomaterials 2010, 31, 4353–4359.Shin, S.; Tuinstra, H.M.; Salvay, D.M.; Shea, L.D. Phosphatidylserine immobilization of lentivirus for localized gene transfer. Biomaterials 2010, 31, 4353–4359, doi:10.1016/j.biomaterials.2010.02.013.
  49. McMahon, S.S.; Nikolskaya, N.; Choileáin, S.N.; Hennessy, N.; O’Brien, T.; Strappe, P.M.; Gorelov, A.; Rochev, Y. Thermosensitive hydrogel for prolonged delivery of lentiviral vector expressing neurotrophin-3 in vitro. J. Gene Med. 2011, 13, 591–601.McMahon, S.S.; Nikolskaya, N.; Choileáin, S.N.; Hennessy, N.; O’Brien, T.; Strappe, P.M.; Gorelov, A.; Rochev, Y. Thermosensitive hydrogel for prolonged delivery of lentiviral vector expressing neurotrophin-3 in vitro. J. Gene Med. 2011, 13, 591–601, doi:10.1002/jgm.1613.
  50. Stilhano, R.S.; Madrigal, J.L.; Wong, K.; Williams, P.A.; Martin, P.K.M.; Yamaguchi, F.S.M.; Samoto, V.Y.; Han, S.W.; Silva, E.A. Injectable alginate hydrogel for enhanced spatiotemporal control of lentivector delivery in murine skeletal muscle. J. Control. Release 2016, 237, 42–49.Stilhano, R.S.; Madrigal, J.L.; Wong, K.; Williams, P.A.; Martin, P.K.M.; Yamaguchi, F.S.M.; Samoto, V.Y.; Han, S.W.; Silva, E.A. Injectable alginate hydrogel for enhanced spatiotemporal control of lentivector delivery in murine skeletal muscle. J. Control. Release 2016, 237, 42–49, doi:10.1016/j.jconrel.2016.06.047.
  51. Skoumal, M.; Seidlits, S.; Shin, S.; Shea, L. Localized lentivirus delivery via peptide interactions. Biotechnol. Bioeng. 2016, 113, 2033–2040.Skoumal, M.; Seidlits, S.; Shin, S.; Shea, L. Localized lentivirus delivery via peptide interactions. Biotechnol. Bioeng. 2016, 113, 2033–2040, doi:10.1002/bit.25961.
  52. Boehler, R.M.; Shin, S.; Fast, A.G.; Gower, R.M.; Shea, L.D. A PLG/HAp composite scaffold for lentivirus delivery. Biomaterials 2013, 34, 5431–5438.Boehler, R.M.; Shin, S.; Fast, A.G.; Gower, R.M.; Shea, L.D. A PLG/HAp composite scaffold for lentivirus delivery. Biomaterials 2013, 34, 5431–5438, doi:10.1016/j.biomaterials.2013.04.009.
  53. Croyle, M.A.; Callahan, S.M.; Auricchio, A.; Schumer, G.; Linse, K.D.; Wilson, J.M.; Brunner, L.J.; Kobinger, G.P. PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. J. Virol. 2004, 78, 912–921.Croyle, M.A.; Callahan, S.M.; Auricchio, A.; Schumer, G.; Linse, K.D.; Wilson, J.M.; Brunner, L.J.; Kobinger, G.P. PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. J. Virol. 2004, 78, 912–921, doi:10.1128/jvi.78.2.912-921.2004.
  54. Munis, A.M.; Mattiuzzo, G.; Bentley, E.M.; Collins, M.K.; Eyles, J.E.; Takeuchi, Y. Use of Heterologous Vesiculovirus G Proteins Circumvents the Humoral Anti-envelope Immunity in Lentivector-Based In Vivo Gene Delivery. Mol. Ther. Nucleic Acids 2019, 17, 126–137.Munis, A.M.; Mattiuzzo, G.; Bentley, E.M.; Collins, M.K.; Eyles, J.E.; Takeuchi, Y. Use of Heterologous Vesiculovirus G Proteins Circumvents the Humoral Anti-envelope Immunity in Lentivector-Based In Vivo Gene Delivery. Mol. Ther. Nucleic Acids 2019, 17, 126–137, doi:10.1016/j.omtn.2019.05.010.
  55. Croyle, M.A.; Yu, Q.-C.; Wilson, J.M. Development of a Rapid Method for the PEGylation of Adenoviruses with Enhanced Transduction and Improved Stability under Harsh Storage Conditions. Hum. Gene Ther. 2000, 11, 1713–1722.Croyle, M.A.; Yu, Q.-C.; Wilson, J.M. Development of a Rapid Method for the PEGylation of Adenoviruses with Enhanced Transduction and Improved Stability under Harsh Storage Conditions. Hum. Gene Ther. 2000, 11, 1713–1722, doi:10.1089/10430340050111368.
  56. Jang, J.-H.; Schaffer, D.V.; Shea, L.D. Engineering biomaterial systems to enhance viral vector gene delivery. Mol. Ther. 2011, 19, 1407–1415.Jang, J.-H.; Schaffer, D.V.; Shea, L.D. Engineering biomaterial systems to enhance viral vector gene delivery. Mol. Ther. 2011, 19, 1407–1415, doi:10.1038/mt.2011.111.
  57. Dalamagkas, K.; Tsintou, M.; Seifalian, A.; Seifalian, A.M. Translational Regenerative Therapies for Chronic Spinal Cord Injury. Int. J. Mol. Sci. 2018, 19, 1776.Dalamagkas, K.; Tsintou, M.; Seifalian, A.; Seifalian, A.M. Translational Regenerative Therapies for Chronic Spinal Cord Injury. Int. J. Mol. Sci. 2018, 19, 1776, doi:10.3390/ijms19061776.
  58. Liu, M.; Huang, C.; Zhao, Z.; Wang, A.; Li, P.; Fan, Y.; Zhou, G. Nano-hydroxyapatite(n-HA) involved in the regeneration of rat nerve injury triggered by overloading stretch. Med. Nov. Technol. Devices 2019, 4, 100022.Liu, M.; Huang, C.; Zhao, Z.; Wang, A.; Li, P.; Fan, Y.; Zhou, G. Nano-hydroxyapatite(n-HA) involved in the regeneration of rat nerve injury triggered by overloading stretch. Med. Nov. Technol. Devices 2019, 4, 100022, doi:10.1016/j.medntd.2019.100022.
  59. Taraballi, F.; Sushnitha, M.; Tsao, C.; Bauza, G.; Liverani, C.; Shi, A.; Tasciotti, E. Biomimetic Tissue Engineering: Tuning the Immune and Inflammatory Response to Implantable Biomaterials. Adv. Healthc. Mater. 2018, 7, 1800490.Taraballi, F.; Sushnitha, M.; Tsao, C.; Bauza, G.; Liverani, C.; Shi, A.; Tasciotti, E. Biomimetic Tissue Engineering: Tuning the Immune and Inflammatory Response to Implantable Biomaterials. Adv. Healthc. Mater. 2018, 7, 1800490, doi:10.1002/adhm.201800490.
  60. Ribeiro-Samy, S.; Silva, N.A.; Correlo, V.M.; Fraga, J.S.; Pinto, L.; Teixeira-Castro, A.; Leite-Almeida, H.; Almeida, A.; Gimble, J.M.; Sousa, N. Development and characterization of a PHB-HV-based 3 D scaffold for a tissue engineering and cell-therapy combinatorial approach for spinal cord injury regeneration. Macromol. Biosci. 2013, 13, 1576–1592.
  61. Papastefanaki, F.; Jakovcevski, I.; Poulia, N.; Djogo, N.; Schulz, F.; Martinovic, T.; Ciric, D.; Loers, G.; Vossmeyer, T.; Weller, H.; et al. Intraspinal Delivery of Polyethylene Glycol-coated Gold Nanoparticles Promotes Functional Recovery After Spinal Cord Injury. Mol. Ther. 2015, 23, 993–1002.Papastefanaki, F.; Jakovcevski, I.; Poulia, N.; Djogo, N.; Schulz, F.; Martinovic, T.; Ciric, D.; Loers, G.; Vossmeyer, T.; Weller, H.; et al. Intraspinal Delivery of Polyethylene Glycol-coated Gold Nanoparticles Promotes Functional Recovery After Spinal Cord Injury. Mol. Ther. 2015, 23, 993–1002, doi:10.1038/mt.2015.50.
  62. Cho, Y.; Shi, R.; Borgens, R.B. Chitosan produces potent neuroprotection and physiological recovery following traumatic spinal cord injury. J. Exp. Biol. 2010, 213, 1513.Cho, Y.; Shi, R.; Borgens, R.B. Chitosan produces potent neuroprotection and physiological recovery following traumatic spinal cord injury. J. Exp. Biol. 2010, 213, 1513, doi:10.1242/jeb.035162.
  63. Shin, S.; Salvay, D.M.; Shea, L.D. Lentivirus delivery by adsorption to tissue engineering scaffolds. J. Biomed. Mater. Res. A 2010, 93, 1252–1259.Shin, S.; Salvay, D.M.; Shea, L.D. Lentivirus delivery by adsorption to tissue engineering scaffolds. J. Biomed. Mater. Res. A 2010, 93, 1252–1259, doi:10.1002/jbm.a.32619.
  64. Bushnell, G.G.; Rao, S.S.; Hartfield, R.M.; Zhang, Y.; Oakes, R.S.; Jeruss, J.S.; Shea, L.D. Microporous scaffolds loaded with immunomodulatory lentivirus to study the contribution of immune cell populations to tumor cell recruitment in vivo. Biotechnol. Bioeng. 2020, 117, 210–222.Brunger, J.M.; Huynh, N.P.T.; Guenther, C.M.; Perez-Pinera, P.; Moutos, F.T.; Sanchez-Adams, J.; Gersbach, C.A.; Guilak, F. Scaffold-mediated lentiviral transduction for functional tissue engineering of cartilage. Proc. Natl. Acad. Sci. USA 2014, 111, E798-E806, doi:10.1073/pnas.1321744111.
  65. Ciciriello, A.J.; Smith, D.R.; Munsell, M.K.; Boyd, S.J.; Shea, L.D.; Dumont, C.M. IL-10 lentivirus-laden hydrogel tubes increase spinal progenitor survival and neuronal differentiation after spinal cord injury. Biotechnol. Bioeng. 2021, 118, 2609–2625.Bushnell, G.G.; Rao, S.S.; Hartfield, R.M.; Zhang, Y.; Oakes, R.S.; Jeruss, J.S.; Shea, L.D. Microporous scaffolds loaded with immunomodulatory lentivirus to study the contribution of immune cell populations to tumor cell recruitment in vivo. Biotechnol. Bioeng. 2020, 117, 210–222, doi:10.1002/bit.27179.
  66. Brunger, J.M.; Huynh, N.P.T.; Guenther, C.M.; Perez-Pinera, P.; Moutos, F.T.; Sanchez-Adams, J.; Gersbach, C.A.; Guilak, F. Scaffold-mediated lentiviral transduction for functional tissue engineering of cartilage. Proc. Natl. Acad. Sci. USA 2014, 111, E798–E806.Schlegel, R.; Tralka, T.S.; Willingham, M.C.; Pastan, I. Inhibition of VSV binding and infectivity by phosphatidylserine: Is phosphatidylserine a VSV-binding site? Cell 1983, 32, 639–646, doi:10.1016/0092-8674(83)90483-x.
  67. Higashikawa, F.; Chang, L.-J. Kinetic Analyses of Stability of Simple and Complex Retroviral Vectors. Virology 2001, 280, 124–131.Boddohi, S.; Moore, N.; Johnson, P.A.; Kipper, M.J. Polysaccharide-based polyelectrolyte complex nanoparticles from chitosan, heparin, and hyaluronan. Biomacromolecules 2009, 10, 1402–1409, doi:10.1021/bm801513e.
  68. Shepard, J.A.; Virani, F.R.; Goodman, A.G.; Gossett, T.D.; Shin, S.; Shea, L.D. Hydrogel macroporosity and the prolongation of transgene expression and the enhancement of angiogenesis. Biomaterials 2012, 33, 7412–7421.Bart, J.; Tiggelaar, R.; Yang, M.; Schlautmann, S.; Zuilhof, H.; Gardeniers, H. Room-temperature intermediate layer bonding for microfluidic devices. Lab Chip 2009, 9, 3481–3488, doi:10.1039/b914270c.
  69. Ehsanipour, A.; Sathialingam, M.; Rad, L.M.; de Rutte, J.; Bierman, R.D.; Liang, J.; Xiao, W.; Di Carlo, D.; Seidlits, S.K. Injectable, macroporous scaffolds for delivery of therapeutic genes to the injured spinal cord. APL Bioeng. 2021, 5, 016104.Ciciriello, A.J.; Smith, D.R.; Munsell, M.K.; Boyd, S.J.; Shea, L.D.; Dumont, C.M. IL-10 lentivirus-laden hydrogel tubes increase spinal progenitor survival and neuronal differentiation after spinal cord injury. Biotechnol. Bioeng. 2021, 118, 2609–2625, doi:10.1002/bit.27781.
  70. Ehsanipour, A.; Nguyen, T.; Aboufadel, T.; Sathialingam, M.; Cox, P.; Xiao, W.; Walthers, C.M.; Seidlits, S.K. Injectable, Hyaluronic Acid-Based Scaffolds with Macroporous Architecture for Gene Delivery. Cell. Mol. Bioeng. 2019, 12, 399–413.Higashikawa, F.; Chang, L.-J. Kinetic Analyses of Stability of Simple and Complex Retroviral Vectors. Virology 2001, 280, 124–131, doi:10.1006/viro.2000.0743.
  71. Kidd, M.E.; Shin, S.; Shea, L.D. Fibrin hydrogels for lentiviral gene delivery in vitro and in vivo. J. Control. Release 2012, 157, 80–85.Shepard, J.A.; Virani, F.R.; Goodman, A.G.; Gossett, T.D.; Shin, S.; Shea, L.D. Hydrogel macroporosity and the prolongation of transgene expression and the enhancement of angiogenesis. Biomaterials 2012, 33, 7412–7421, doi:10.1016/j.biomaterials.2012.06.081.
  72. Gros, T.; Sakamoto, J.S.; Blesch, A.; Havton, L.A.; Tuszynski, M.H. Regeneration of long-tract axons through sites of spinal cord injury using templated agarose scaffolds. Biomaterials 2010, 31, 6719–6729.Ehsanipour, A.; Sathialingam, M.; Rad, L.M.; de Rutte, J.; Bierman, R.D.; Liang, J.; Xiao, W.; Di Carlo, D.; Seidlits, S.K. Injectable, macroporous scaffolds for delivery of therapeutic genes to the injured spinal cord. APL Bioeng. 2021, 5, 016104–016104, doi:10.1063/5.0035291.
  73. Smith, D.R.; Dumont, C.M.; Park, J.; Ciciriello, A.J.; Guo, A.; Tatineni, R.; Cummings, B.J.; Anderson, A.J.; Shea, L.D. Polycistronic Delivery of IL-10 and NT-3 Promotes Oligodendrocyte Myelination and Functional Recovery in a Mouse Spinal Cord Injury Model. Tissue Eng. Part A 2020, 26, 672–682.Ehsanipour, A.; Nguyen, T.; Aboufadel, T.; Sathialingam, M.; Cox, P.; Xiao, W.; Walthers, C.M.; Seidlits, S.K. Injectable, Hyaluronic Acid-Based Scaffolds with Macroporous Architecture for Gene Delivery. Cell. Mol. Bioeng. 2019, 12, 399–413, doi:10.1007/s12195-019-00593-0.
  74. Smith, D.R.; Margul, D.J.; Dumont, C.M.; Carlson, M.A.; Munsell, M.K.; Johnson, M.; Cummings, B.J.; Anderson, A.J.; Shea, L.D. Combinatorial lentiviral gene delivery of pro-oligodendrogenic factors for improving myelination of regenerating axons after spinal cord injury. Biotechnol. Bioeng. 2019, 116, 155–167.Gros, T.; Sakamoto, J.S.; Blesch, A.; Havton, L.A.; Tuszynski, M.H. Regeneration of long-tract axons through sites of spinal cord injury using templated agarose scaffolds. Biomaterials 2010, 31, 6719–6729, doi:10.1016/j.biomaterials.2010.04.035.
  75. Tuinstra, H.M.; Margul, D.J.; Goodman, A.G.; Boehler, R.M.; Holland, S.J.; Zelivyanskaya, M.L.; Cummings, B.J.; Anderson, A.J.; Shea, L.D. Long-Term Characterization of Axon Regeneration and Matrix Changes Using Multiple Channel Bridges for Spinal Cord Regeneration. Tissue Eng. Part A 2013, 20, 1027–1037.Smith, D.R.; Dumont, C.M.; Park, J.; Ciciriello, A.J.; Guo, A.; Tatineni, R.; Cummings, B.J.; Anderson, A.J.; Shea, L.D. Polycistronic Delivery of IL-10 and NT-3 Promotes Oligodendrocyte Myelination and Functional Recovery in a Mouse Spinal Cord Injury Model. Tissue Eng. Part A 2020, 26, 672–682, doi:10.1089/ten.tea.2019.0321.
  76. Smith, D.R.; Margul, D.J.; Dumont, C.M.; Carlson, M.A.; Munsell, M.K.; Johnson, M.; Cummings, B.J.; Anderson, A.J.; Shea, L.D. Combinatorial lentiviral gene delivery of pro-oligodendrogenic factors for improving myelination of regenerating axons after spinal cord injury. Biotechnol. Bioeng. 2019, 116, 155–167, doi:10.1002/bit.26838.
  77. Kidd, M.E.; Shin, S.; Shea, L.D. Fibrin hydrogels for lentiviral gene delivery in vitro and in vivo. J. Control. Release 2012, 157, 80–85, doi:10.1016/j.jconrel.2011.08.036.
  78. Tuinstra, H.M.; Margul, D.J.; Goodman, A.G.; Boehler, R.M.; Holland, S.J.; Zelivyanskaya, M.L.; Cummings, B.J.; Anderson, A.J.; Shea, L.D. Long-Term Characterization of Axon Regeneration and Matrix Changes Using Multiple Channel Bridges for Spinal Cord Regeneration. Tissue Eng. Part A 2013, 20, 1027–1037, doi:10.1089/ten.tea.2013.0111.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Feedback